Joel Beatty
Stock Analyst at Baird
(4.60)
# 240
Out of 5,113 analysts
200
Total ratings
52.17%
Success rate
33.89%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $72 → $47 | $24.44 | +92.31% | 5 | Dec 30, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $14.43 | -2.98% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $165.41 | +26.35% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $84.98 | +47.09% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $14.51 | +30.99% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.68 | +90.22% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $50.50 | +32.67% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.06 | +191.26% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $38.36 | -76.54% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $25.62 | +21.00% | 4 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $24 | $19.27 | +24.55% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $846.76 | -19.69% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $20.84 | +39.16% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $75.60 | -12.70% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $185.17 | -12.51% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $33.90 | +20.94% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $309.92 | -76.45% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $24.20 | +32.23% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $80.24 | -6.53% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $3.06 | +128.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $56.68 | +14.68% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.03 | +23,200.97% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.33 | +238.35% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $17.87 | +39.90% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $20.55 | +36.25% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.61 | +893.79% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.55 | -19.35% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.25 | +3,420.00% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $65.58 | -11.56% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $33.65 | -28.68% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $7.37 | +144.23% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $1.62 | +270.37% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $7.57 | +269.88% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $349.58 | -49.94% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $7.69 | +82.05% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $21.31 | +406.80% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $81.92 | -4.79% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $23.77 | +320.70% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.07 | +696.28% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.62 | +12,330.94% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.46 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $9.23 | +62.51% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $0.46 | +260,260.16% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $8.04 | +136.32% | 3 | Nov 10, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72 → $47
Current: $24.44
Upside: +92.31%
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $14.43
Upside: -2.98%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $165.41
Upside: +26.35%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $84.98
Upside: +47.09%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $14.51
Upside: +30.99%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.68
Upside: +90.22%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $50.50
Upside: +32.67%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.06
Upside: +191.26%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $38.36
Upside: -76.54%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $25.62
Upside: +21.00%
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.27
Upside: +24.55%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $846.76
Upside: -19.69%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $20.84
Upside: +39.16%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $75.60
Upside: -12.70%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $185.17
Upside: -12.51%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $33.90
Upside: +20.94%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $309.92
Upside: -76.45%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $24.20
Upside: +32.23%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $80.24
Upside: -6.53%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $3.06
Upside: +128.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $56.68
Upside: +14.68%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.03
Upside: +23,200.97%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.33
Upside: +238.35%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $17.87
Upside: +39.90%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $20.55
Upside: +36.25%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.61
Upside: +893.79%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.55
Upside: -19.35%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.25
Upside: +3,420.00%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $65.58
Upside: -11.56%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $33.65
Upside: -28.68%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $7.37
Upside: +144.23%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $1.62
Upside: +270.37%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $7.57
Upside: +269.88%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $349.58
Upside: -49.94%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $7.69
Upside: +82.05%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $21.31
Upside: +406.80%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $81.92
Upside: -4.79%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $23.77
Upside: +320.70%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.07
Upside: +696.28%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.62
Upside: +12,330.94%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.46
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $9.23
Upside: +62.51%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $0.46
Upside: +260,260.16%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $8.04
Upside: +136.32%